40 Erie Street
Tel: (857) 285-6200
About Intellia Therapeutics
Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.
Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.
We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.
Change life stories with genome editing therapies!
Stock Symbol: NTLA
Check out our Intellia office space!
118 articles with Intellia Therapeutics
NTLA-5001 is being developed for the treatment of acute myeloid leukemia (AML).
Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia
Intellia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted the investigational new drug (IND) application for NTLA-5001, the company’s first wholly-owned ex vivo CRISPR genome editing candidate for the treatment of cancer.
9/7/2021Is your job burning you out? According to BioSpace's recent research, approximately 70% of biotech professionals feel burned out. Is it time to look for a new job? The good news is that biotech companies keep adding jobs and the market is hot! Check out these hot companies that are looking for c...
On June 26, Intellia announced the first-ever clinical data supporting the safety and efficacy of in vivo CRISPR genome editing in human patients.
Intellia Therapeutics, Inc. will present at the following virtual healthcare investor conferences in September: Thursday, September 9, 2021 Wells Fargo Healthcare Conference Time: 10:40 am ET
Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress
Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, reported financial results for the second quarter ended June 30, 2021, and recent operational highlights.
With this milestone, the field is now wide open for the next in vivo CRISPR success, and Editas is hoping that it will be in the ocular disease space.
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates
Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its second quarter 2021 financial results and operational highlights in a conference call on August 5, 2021 at 8 a.m. E.T.
7/7/2021The long weekend didn't slow down the IPO train barreling down the tracks. More life sciences companies announced and closed their initial public offerings, bringing millions more to their coffers.
This appears to be a second example of CRISPR gene editing inside the body, as opposed to in cell cultures.
7/6/2021It was another busy week for clinical trial news ahead of the July 4 holiday in the U.S. Here’s a look.
Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced the closing of an underwritten public offering of 4,758,620 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 620,689 shares, at the public offering price of $145.00 per share.
Jennifer Doudna is best known for discovering CRISPR/Cas9 gene editing with Emmanuelle Charpentier, and both winning the Nobel Prize in Chemistry in 2020.
Cambridge, Mass.-based Intellia Therapeutics has had a busy week, but they’re topping it off with the announcement of their public offering price of $145 per share for 4,137,931 shares.
Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced the pricing of an underwritten public offering of 4,137,931 shares of its common stock at a public offering price of $145.00 per share.
Interim results from the Phase I study presented at the Peripheral Nerve Society Annual Meeting demonstrated that the investigational therapy, NTLA-2001, greatly reduced the disease-causing protein after a single infusion.
Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced that it has commenced an underwritten public offering of $400 million of shares of its common stock.
Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis
Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. announced positive interim data from an ongoing Phase 1 clinical study of their lead in vivo genome editing candidate, NTLA-2001, which is being developed as a single-dose treatment for transthyretin amyloidosis.
In what will be a big moment for CRISPR technology, Intellia and development partner, Regeneron Pharmaceuticals will share the world’s first data from a therapy that edits flawed genes inside the body.
Intellia Therapeutics Names James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary
Intellia Therapeutics, Inc. today announced the appointment of James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary.